viewAchieve Life Sciences Inc

Achieve Life Sciences shares rise as data safety committee finds no issues with smoking cessation trial

The plant-based compound interacts with the brain’s nicotine receptors to reduce withdrawal symptoms

Cigarette butt
Stubbing it out ... the trial is looking at the smoking-cessation drug cytisinicline

Achieve Life Sciences Inc (NASDAQ:ACHV) shares swirled a bit higher Tuesday as the biotech revealed that the data safety monitoring committee (DSMC) had no issues with its trial of smoking-cessation drug cytisinicline.

The Phase 2b trial called ORCA-1 should continue, it said, while topline efficacy and safety data are expected by the end of the second quarter of 2019.

READ: Achieve Life Sciences shares rocket after a promising smoking-cessation drug trial

Cytisinicline is a plant-based alkaloid and has been an approved, branded product in Central and Eastern Europe for more than two decades to help combat nicotine addiction.

The data safety committee has reviewed the ORCA-1 data twice during the study, and has concluded following each review that there are no safety concerns for subjects or study conduct issues.

The trial is evaluating a 25-day treatment course of 1.5 mg or 3 mg doses of cytisinicline using either a declining titration schedule or three times daily. The trial is randomized and blinded to compare the effectiveness of the cytisinicline doses and schedules to respective placebo groups.

The primary efficacy endpoint is the overall reduction in the number of cigarettes smoked during the treatment period.

Shares in Achieve Life Sciences added 1.8% in New York to stand at $3.23

Quick facts: Achieve Life Sciences Inc

Price: 0.4083 USD

Market: NASDAQ
Market Cap: $15.32 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...



ioneer Ltd's Bernard Rowe hails new boric acid distribution and sales agreements

ioneer Ltd's (ASX:INR) Bernard Rowe speaks to Proactive's Andrew Scott after securing two distribution and sales agreements for the supply of boric acid from its Rhyolite Ridge Lithium-Boron Project in Nevada, USA. The three-year boric acid distribution and sales agreements were signed with...

17 hours, 27 minutes ago

2 min read